For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
2
views
5
references
 Top references
cited by
3
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      67
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Access in all areas? A round up of developments in market access and health technology assessment: part 1

      discussion

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In this new series reviewing recent developments in market access, we highlight publications investigating health technology assessment (HTA) guidance, review processes and outcomes across the world and discuss how forthcoming changes in the HTA and regulatory environment in the European Union may allow for more consistency in decision making.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: not found

          Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]

          Patricia Danzon, Anirban Basu, Charles E. Phelps … (2018)
          The third section of our Special Task Force report identifies and defines a series of elements that warrant consideration in value assessments of medical technologies. We aim to broaden the view of what constitutes value in health care and to spur new research on incorporating additional elements of value into cost-effectiveness analysis (CEA). Twelve potential elements of value are considered. Four of them-quality-adjusted life-years, net costs, productivity, and adherence-improving factors-are conventionally included or considered in value assessments. Eight others, which would be more novel in economic assessments, are defined and discussed: reduction in uncertainty, fear of contagion, insurance value, severity of disease, value of hope, real option value, equity, and scientific spillovers. Most of these are theoretically well understood and available for inclusion in value assessments. The two exceptions are equity and scientific spillover effects, which require more theoretical development and consensus. A number of regulatory authorities around the globe have shown interest in some of these novel elements. Augmenting CEA to consider these additional elements would result in a more comprehensive CEA in line with the "impact inventory" of the Second Panel on Cost-Effectiveness in Health and Medicine. Possible approaches for valuation and inclusion of these elements include integrating them as part of a net monetary benefit calculation, including elements as attributes in health state descriptions, or using them as criteria in a multicriteria decision analysis. Further research is needed on how best to measure and include them in decision making.
          Article 0 comments Cited 158 times – based on 0 reviews     Review now
          Article has an altmetric score of 80
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.

            Laia Maynou, John Cairns (2019)
            Decisions on the reimbursement of the same cancer drugs are different across European countries, but empirical work on the reasons behind these differences has been scarce. The main objective of this paper is to make a methodological contribution to existing research, specifically by outlining the systematic process of analysis to address such questions and determining the factors that might lead to different drug reimbursement decisions, and to explore its application in the field of oncology.
            Article 0 comments Cited 16 times – based on 0 reviews     Review now
            Article has an altmetric score of 8
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study

              Kristina Jenei, Adam J N Raymakers, Arnaud Bayle … (2023)
              Article 0 comments Cited 14 times – based on 0 reviews     Review now
              Article has an altmetric score of 95
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): J Comp Eff Res
                Journal ID (iso-abbrev): J Comp Eff Res
                Journal ID (publisher-id): CER
                Title: Journal of Comparative Effectiveness Research
                Publisher: Becaris Publishing Ltd (Royston, UK )
                ISSN (Print): 2042-6305
                ISSN (Electronic): 2042-6313
                Publication date (Electronic, pub): 16 August 2023
                Publication date (Electronic, collection): October 2023
                Publication date PMC-release: 16 August 2023
                Volume: 12
                Issue: 10
                Electronic Location Identifier: e230129
                Affiliations
                [1 ]MSD Innovation & Development, Zurich, 8058, Switzerland
                [2 ]Lane Clark & Peacock, London, W1U 1DQ, UK
                [3 ]BeiGene, London, EC4A 4AB, UK
                [4 ]Centre for Pharmaceutical Medicine Research, King's College London, SE1 9NH, UK
                Author notes
                [* ]Author for correspondence: sreeram.ramagopalan@ 123456lcp.uk.com
                Article
                DOI: 10.57264/cer-2023-0129
                PMC ID: 10690433
                PubMed ID: 37584405
                SO-VID: 2aed0f70-30ef-4a53-88d0-0728e8aee8c5
                Copyright © © 2023 The Authors
                License:

                This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License

                History
                Date received : 10 July 2023
                Date accepted : 03 August 2023
                Date: 16 August 2023
                Page count
                Pages: 3
                Categories
                Subject: Industry Update

                Keywords: decision making,european union,health technology assessment,joint clinical assessment,market access,regulatory
                Data availability:
                Keywords: decision making, european union, health technology assessment, joint clinical assessment, market access, regulatory

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content67

                See all similar

                Cited by3

                See all cited by

                Most referenced authors42

                See all reference authors